Generic Name and Formulations:
Nusinersen 12mg/5mL; soln for intrathecal inj; preservative-free.
Indications for SPINRAZA:
Spinal muscular atrophy.
Adults and Children:
Consider sedation and ultrasound or other imaging techniques as guidance. Remove 5mL of cerebrospinal fluid prior to inj. Give as intrathecal bolus inj over 1–3 mins. 12mg (5mL) per dose. Initially: give 3 loading doses at 14-day intervals then give 4th loading dose 30 days after. Maintenance: give dose once every 4 months thereafter.
Do not administer in areas of infected or inflamed skin. Increased risk of bleeding complications. Perform platelet count, prothrombin time, aPTT, quantitative spot urine protein testing at baseline, prior to each dose, and as clinically needed; consider repeat testing if urine protein >0.2g/L. Pregnancy. Nursing mothers.
Lower/upper respiratory infection, constipation, teething; thrombocytopenia, coagulation abnormalities, renal toxicity.
Neurology Advisor Articles
- Migraine and Gastrointestinal Disorders: Elucidating an Association
- Alzheimer's Disease Risk Similar in Women and Men With APOE ε3/ε4 Genotype
- Non-Invasive Magnetic Device Approved by FDA for Migraine Tx
- Multiple Sclerosis Risk Significantly Associated With Vitamin D Deficiency
- FDA Approves Device for Tx of Chronic Pain
- Defining Unique Needs for Palliative and Hospice Care in Huntington Disease
- ENCHANTED Update: No Role for Low-Dose Alteplase After All?
- Gender Plays a Role in Autism Spectrum Disorder Recurrence Among Siblings
- Prescription, OTC Sleep Medications Often Used in Older Adults
- Medicare Boosted Restrictions on Opioids From 2006-2015